{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:19:31Z","timestamp":1791231571583,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T00:00:00Z","timestamp":1201737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2008,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the prevalence of anticardiolipin antibodies (aCL), anti\u2013\u03b2<jats:sub>2<\/jats:sub>\u2010glycoprotein I (anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI) antibodies, and lupus anticoagulant (LAC) in a large cohort of children with systemic lupus erythematosus (SLE), and to evaluate the associations with neuropsychiatric manifestations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single\u2010center retrospective cohort study with longitudinal followup of antiphospholipid antibodies (aPL) in 137 children with SLE (25 boys and 112 girls, mean age at diagnosis 13.0 years) was performed. Patients were followed up for a mean of 31 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At the time of diagnosis, 65% of the children were aCL positive, 41% had anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI antibodies, and 26% were LAC positive. Analysis of the association between presence of aPL and individual neuropsychiatric manifestations at diagnosis showed a statistically significant association of positive LAC with cerebrovascular disease (5 patients; <jats:italic>P<\/jats:italic> = 0.015). A persistently positive aCL was observed in 50%, anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI antibodies in 29%, and LAC in 16% of children over time. The prevalence of anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI antibodies, but not aCL and LAC, was found to be statistically significantly higher in children with neuropsychiatric disease compared with those without (<jats:italic>P<\/jats:italic> = 0.02). Comparison for specific neuropsychiatric manifestations showed a statistically significant association between a persistently positive LAC and chorea (2 patients; <jats:italic>P<\/jats:italic> = 0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The prevalence of anti\u2010\u03b2<jats:sub>2<\/jats:sub>GPI antibodies was found to be higher in the group of SLE patients with neuropsychiatric disease compared with those without. Our data suggest an association between LAC and cerebrovascular disease at the time of SLE diagnosis and chorea over the disease course, but not between aPL and other neuropsychiatric manifestations.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.23334","type":"journal-article","created":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T18:48:22Z","timestamp":1201805302000},"page":"206-213","source":"Crossref","is-referenced-by-count":94,"title":["A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus"],"prefix":"10.1002","volume":"59","author":[{"given":"Tadej","family":"Av\u010din","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Benseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal N.","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161a","family":"\u010cu\u010dnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl D.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0887-8994(95)00186-J"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307380001501207"},{"key":"e_1_2_6_4_2","first-page":"1536","article-title":"The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus","volume":"29","author":"Sibbitt WL","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390420"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199810)41:10<1819::AID-ART14>3.0.CO;2-Y"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/08916930290016547"},{"key":"e_1_2_6_8_2","first-page":"985","article-title":"Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies","volume":"30","author":"Sanna G","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1198"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80188-0"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119572"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120399678847524"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1892"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu458oa"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2048"},{"key":"e_1_2_6_16_2","first-page":"1873","article-title":"Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies","volume":"33","author":"Harel L","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973766"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01954739"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00273-X"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.00701.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2272rr"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199907)42:7<1354::AID-ANR8>3.0.CO;2-4"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10072"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649901"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.5.565"},{"key":"e_1_2_6_31_2","first-page":"1977","article-title":"Summarizing disease features over time. I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus","volume":"30","author":"Ibanez D","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11205"},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1542\/peds.96.6.1040","article-title":"Antiphospholipid antibodies in pediatric systemic lupus erythematosus","volume":"96","author":"Seaman DE","year":"1995","journal-title":"Pediatrics"},{"key":"e_1_2_6_34_2","first-page":"1389","article-title":"The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus","volume":"15","author":"Shergy WJ","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1994.02170040064011"},{"key":"e_1_2_6_36_2","first-page":"766","article-title":"Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus","volume":"28","author":"Mok CC","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu503oa"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(98)00027-6"},{"key":"e_1_2_6_39_2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1160\/TH03-10-0608","article-title":"Strong correlation between the prevalence of cerebral infarction and the presence of anti\u2010cardiolipin\/beta2\u2010glycoprotein I and anti\u2010phosphatidylserine\/prothrombin antibodies: co\u2010existence of these antibodies enhances ADP\u2010induced platelet activation in vitro","volume":"91","author":"Nojima J","year":"2004","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.47.8.681"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199705000-00006"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973468"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-003-1388-6"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu392oa"},{"key":"e_1_2_6_45_2","first-page":"280","article-title":"Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus\u2010like disease: good functional outcome and relevance of antiphospholipid antibodies","volume":"31","author":"D'Cruz DP","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh384"},{"key":"e_1_2_6_47_2","first-page":"1067","article-title":"Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus","volume":"21","author":"Drenkard C","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.1.77"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.23334","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.23334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T22:41:39Z","timestamp":1696977699000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.23334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,31]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2,15]]}},"alternative-id":["10.1002\/art.23334"],"URL":"https:\/\/doi.org\/10.1002\/art.23334","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,31]]}}}